Camilla Soenderby

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.

Part of Merck & Co., Inc., Schering-Plough Ltd. (Taiwan) is a Taiwanese company that sells and supplies pharmaceutical products. The company is based in Taipei, Taiwan.

Part of AbbVie, Inc., AbbVie SAS (France) is a health endowment fund that supports general and innovative health projects in therapeutic areas such as virology, oncology, immunology, and neuroscience. The company is based in Rungis, France. The French company encourages actors in the field to improve the patient's journey and trust them. The company was founded in 2012. Sylvie Gregoire Huguel has been the CEO of the company since 2018.

Shire France SA manufactures pharmaceutical products. The firm offers prescriptions and proprietary drugs. It specializes in therapeutic areas such as hematology, nephrology, central nervous system, gastrointestinal, and genetic diseases. The company was founded in 1997 and is headquartered in Paris, France.